1. These guidelines are limited to non-Japanese ophthalmologists living outside of Japan who would like to submit abstracts as "international members".
2. The chair of program committee has the authority to make final decisions such as the acceptance or rejection of the abstract and the determination of presentation format.
3. The presentations will be made on site. The presentations cannot be made remotely.
4. Please note that 79th RINGAN covers clinical and clinically relevant basic content and does not adopt purely basic content.
5. All abstract applicants are required to create a user account first.
6. Once the submission is completed, you will receive automatically delivered e-mail confirming the receipt of your abstract. If you do not receive above e-mail within 24 hours after submission, please contact the Conference Secretariat (79ringan@jtbcom.co.jp).
7. Abstract number will be generated automatically when an abstract is submitted. For changes, withdrawal and additional submission of abstract, please log in with your ID and password by clicking "Abstract Submission" at the bottom of this page.

1. Select the style of presentation

● Free Paper Presentation:

● Poster Presentation:

A free discussion is set up with the participants.

1. Papers that have been or will be presented in other ophthalmology-related academic meetings in Japan cannot be accepted.
   However, the following categories of papers will be treated as exceptions: specialized presentations (symposium, educational seminar, etc.), and papers presented at international academic meetings (in case of presentation at an international meeting convened in Japan, acceptable only if presented in English).
2. A presenter may make only one general presentation, as the first author.
3. The title should be no longer than 80 characters including spaces, affiliation should be concise and the abstract no longer than 1200 characters including spaces. The shortened title should be no longer than 30 characters including spaces.
4. The abstract should be structured with the following headings:,- Objective, Subjects and Methods, Results, and Conclusions, in that order. For case reports and invention or improvement of techniques and devices, the headings should be appropriately changed (for example, for case reports, Introduction, Cases, Discussion and, if relevant, Conclusions).
5. Methods, Results, etc. should be described clearly, with numerical values and the statistical analysis methods used, where possible. Invention or improvement of techniques and devices should also be described clearly.
6. The Conclusion and Discussion should correspond to the Results described.
7. Common names should be used for chemicals. Trade names should be given (……®) after the common names, if necessary (Example: timolol maleate [Timoptol®]).
8. Presentations, abstracts and presentation data must be prepared in English.
9. See below for disclosure of conflict of interests.
10. On abstract submission form, please select whether you have obtained an approval of the ethics committee, e.g. IRB, or if it is not necessary. This does not need to be stated in the abstract text.
11. Regarding an approval of the animal research and ethics committee, e.g. IACUC, please select whether you have obtained an approval of the committee or not necessary on the abstract submission form. The author is not required to mention it in the abstract body.
12. On abstract submission form, please select whether you have obtained an informed consent or if it is not necessary. This does not need to be stated in the abstract text.

When making a presentation at the Annual Meeting of the Japanese Ophthalmological Society and the Annual Congress of Japan Clinical Ophthalmology, the authors have to report any conflict of interest based on “the rules for conflict of interest of Japanese Ophthalmological Society." If the presentation is accepted, the category of conflict of interest and company names must be disclosed in the slide and poster for presentation, based on “the rules for conflict of interest of Japanese Ophthalmological Society."

A. Presentations to Which These Rules are Applicable
These rules are applicable to all presentations, including those in Co-Sponsored Seminars, Special Lectures, Invited Lectures, Symposia, Instruction Courses, General Presentations (including posters), etc.,

B. Report on Conflict of Interest at Abstract Submission
Report the potential conflict of interest with companies within the last three years no matter whether it's concerned with or without the content of your presentation. If conflict of interest is “present," enter the category, class and company names after each author's name in the entry field of “Conflict of Interest" on the abstract submission form. If conflict of interest is absent, enter “category N." Confirm the declaration is correct prior to the registration. Categories and classes are as follows.

F (Financial Support):
In the case where research expenses are supported or free research materials (including devices) or services (including sample measurements) are provided by companies (*) through the organization to which the author belongs.
(*) Companies denote both related companies and competitor companies. This is also the case for all subsequent categories.

I (Personal Financial Interest):
In the case where the author is an investor in a company related to the chemicals and materials (including devices) used and services are provided.

E (Employee):
In the case where the author is an employee of an interested company.

C (Consultant):
In the case where the author is currently, or was within the past three years, a consultant of an interested company.

P (Patent):
In the case where the author holds a patent or is in the process of applying for a patent.

R :
In the case where the author receives rewards (*) or travel expenses from a company related to the chemicals and materials (including devices) used and services provided. (*) Rewards include salaries, travel fees, intellectual property rights, royalties, honoraria, shares, stock options, consultancy fees, lecture fees, expenses as a member of advisory committees and review panels, etc.

1. 0 yen
2. From 1 to less than 500,000 yen
3. From 500,000 to 5,000,000 yen
4. Over 5,000,000 yen

* Conflict of interest should be disclosed for the fiscal year during the previous three years when the author received the largest sum of money.

C. Disclosure in the Abstract and Slide
Abstract:
The presence or absence of conflict of interest to be disclosed for the author (including co-authors) will be automatically shown at the end of the abstract, according to “the detailed rules of the standard for disclosure in the Japanese Ophthalmological Society." For categories F, C and R, only class IV (over 5,000,000 yen) will be correspond to “presence".

Slide and poster:
If the authors have to disclose any conflict of interest, the category and company names* should be described after the authors' names in the second slide and at the end of the poster. For categories F, C and R, only class IV (over 5,000,000 yen) should be disclosed.

Please contact the conference secretariat for any questions by e-mail or FAX (not by telephone).